Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Harry Masuda | M | 79 |
Human BioSystems, Inc.
 Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| George Tsukuda | M | - |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| Larry McCleary | M | 73 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | 4 Jahre |
| Robert E. Strom | M | - |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| Luis H. Toledo-Pereyra | M | 79 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | 9 Jahre |
| Rachmat M. Umar | M | - |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| David Winter | M | 89 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | 4 Jahre |
| Frank J. Drechsler | M | 57 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 8 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Paul Okimoto
- Persönliches Netzwerk
